Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization

Blood

Volumn 91, Issue 9, 1998, Pages 3289-3299

  Perollet, Catherine ^b   Han, Zhong Chao ^b   Savona, Catherine ^b   Caen, Jacques Philippe ^b   Bikfalvi, Andreas ^a  

^a Lab Facteurs Croissance D   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; THROMBOCYTE FACTOR 4;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SEQUENCE HOMOLOGY; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

EID: 2642708372     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.9.3289     Document Type: Article

References (51)

1. Bikfalvi A, Klein S, Pintucci G, Rifkin, DB: Biological roles of fibroblast growth factor-2. Endocr Rev 18:26, 1997
2. Ferrara N, Davis-Smyth T: New insights in the biology of vascular endothelial growth factor. Endocr Rev 18:4, 1997
3. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353, 1996
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315, 1994
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277, 1997
6. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582, 1994
7. Ferrara N, Clapp C, Weiner R: The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129:896, 1991
8. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77, 1990
9. Stricter RM, Polverini PJ, Arenberg DA, Kunkel SL: The role of CXC chemokines as regulators of angiogenesis. Shock 4:155, 1995
10. Deuel TF, Keim PF, Farmer M, Heinrickson RL: Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 74:2256, 1977
11. Miller MD, Krangel MS: Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 12:17, 1992
12. Zhang X, Chen L, Bancroft DL, Lai CK, Maione TM: Crystal structure of recombinant human platelet factor 4. Biochemistry 33: 8361, 1994
13. Han ZC, Sensebé L, Abgrall JF, Brière J: Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 75:1234, 1990
14. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M: Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N-terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA 90:3574, 1993
15. Crisi GM, Katz IR, Zucker MB, Thorbecke GJ: Induction of inhibitory activity for B cell differentiation in human CD8 T cells with pokeweed mitogen, dimaprit, and cAMP upregulating agents: Countersuppressive effect of platelet factor-4. Cell Immunol 172:205, 1996
16. Gupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 127:1121, 1994
17. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor-4. J Natl Cancer Inst 82:848, 1990
18. Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor-4. J Natl Cancer Inst 87:304, 1995
19. Tanaka T, Manome Y, Wen P, Kufe D, Fine HA: Viral vector-mediated transduction of a modified platelet factor-4 cDNA inhibits angiogenesis and tumor growth. Nat Med 3:437, 1997
20. Hansell P, Maione TE, Borgstrom P: Selective binding of platelet factor-4 to regions of active angiogenesis in vivo. Am J Physiol 269:829, 1995
21. Watson JB, Getzler SB, Mosher DF: Platelet factor-4 modulates the mitogenic activity of basic fibroblast growth factor. J Clin Invest 94:261, 1994
22. Sato Y, Abe M, Takaki R: Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 172:595, 1990
23. Brown KJ, Parish CR: Histidine-rich glycoprotein and platelet factor-4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 33:13918, 1994
24. Luster AD, Greenberg SM, Leder P: The IP-1O chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182:219, 1997
25. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, Maione TE, Levi BZ, Neufeld G: Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 270:15059, 1995
26. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB: Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: Possible intracellular signaling by the high molecular weight forms. J Cell Biol 129:233, 1995
27. Moscatelli D: High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 131:123, 1987
28. Roghani M, Moscatelli D: Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 267:22156, 1992
29. Ornitz DM, Yayon A, Flanagan JG, Svan CM, Levi E, Leder P: Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12:240, 1992
30. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz D: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841, 1991
31. Li LY, Safran M, Aviezer D, Bohlen P, Seddon AP, Yayon A: Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry 33:10999, 1994
32. Files JC, Melpas JW, Yee EK, Ritchie JL, Harker LA: Studies of human plate alpha-granule release in vivo. Blood 58:607, 1981
33. Roghani M, Mansukhani A, Dell'Era P, Bellosta P, Basilico C, Rifkin DB, Moscatelli D: Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 269:3976, 1994
34. Yan Z, Zhang J, Holt JC, Stewart GJ, Niewiarowski S, Poncz M: Structural requirements of platelet chemokines for neutrophil activation. Blood 84:2329, 1994
35. Hanneken A, Maher PA, Baird A: High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells - Implications for the modulation of FGF-2. J Cell Biol 128:1221, 1995
36. Vlodavsky I, Miao HQ, Atzmon R, Levi E, Zimmermann J, Bar-Shavit R, Peretz T, Ben-Sasson SA: Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Thromb Haemost 74:534, 1995
37. Aviezer D, Iozzo RV, Noonan DM, Yayon A: Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 17:1938, 1997
38. Steinfeld R, Van Den Berghe H, David G: Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 133:405, 1996
39. Song HH, Shi W, Filmus J: OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 272:7574, 1997
40. Kojima T, Katsumi A, Yamazaki T, Muramatsu T, Nagasaka T, Ohsumi K, Saito H: Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem 271:5914, 1996
41. Dennis PA, Saksela O, Harpel P, Rifkin DB: Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. J Biol Chem 264:7210, 1989
42. Schlessinger J, Lax I, Lemmon M: Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 83:357, 1995
43. Moy FJ, Safran M, Seddon AP, Kitchen D, Bohlen P, Aviezer D, Yayon A, Powers R: Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry 36:4782, 1997
44. Venkataraman G, Sasisekharan V, Herr AB, Ornitz DM, Waksman G, Cooney CL, Langer R, Sasisekharan R: Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci USA 93:845, 1996
45. Gupta SK, Hassel T, Singh JP: A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92:7799, 1995
46. Maione TE, Gray GS, Hunt AJ, Sharpe RJ: Inhibition of tumor growth in mice by an analogue of platelet factor-4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 51:2077, 1991.
47. Mayo KH, Ilyina E, Roongta V, Dundas M, Joseph J, Lai CK, Maione TE, Daly TJ: Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: Arginine residues are crucial for binding. Biochem J 312:357, 1995
48. Moscatelli D, Quarto N: Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes down-regulation of the fibroblast growth factor receptor: Reversal of morphological transformation and restoration of receptor number by suramin. J Cell Biol 109:2519, 1989
49. Gagliardi AR, Collins DC: Inhibition of angiogenesis by aurintricarboxylic acid. Anticancer Res 14:475, 1994
50. Taraboletti G, Belotti D, Borsotti P, Rusnati M, Presta M, Giavazzi R: The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8:471, 1997
51. Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky IJ: Modulation of tibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparinmimicking polyanionic compound. J Clin Invest 99:1565, 1997